Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 504.34% and ...

While other big pharmas have faltered, Lilly made headway in a Phase 3 trial that could provide a treatment option to replace ...

Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy ...

It looks like Eli Lilly’s oral selective estrogen receptor degrader (SERD) imlunestrant may need some extra help to reach a ...

With a positive phase 3 trial in chronic lymphocytic leukemia (CLL), Eli Lilly hopes to convert Jaypirca’s unique accelerated ...

A national medical firm has announced it will launch a $3 billion expansion of its Kenosha County facility and will bring 750 ...

Eli Lilly (LLY) closed at $796.03 in the latest trading session, marking a -0.44% move from the prior day. The stock fell short of the S&P 500, which registered a gain of 0.82% for the day. Elsewhere, ...

David Ricks, the chair and chief executive of Eli Lilly, speaking at The New York Times’s DealBook Summit, said his $750 ...

The U.K. will soon offer Eli Lilly's Mounjaro for people with obesity — but only to a small share of those medically eligible ...

Eli Lilly said on Wednesday patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo ...